Cargando…

Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis

To investigate whether serum leucine-rich α2-glycoprotein (LRG) levels are useful as a marker of disease activity in systemic juvenile idiopathic arthritis (s-JIA), we determined serum LRG levels in fifty-nine s-JIA patients, 15 with other subtypes of JIA, 7 with Kawasaki disease (KD), 7 with influe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Masaki, Inoue, Natsumi, Mizuta, Mao, Nakagishi, Yasuo, Yachie, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378769/
https://www.ncbi.nlm.nih.gov/pubmed/30863782
http://dx.doi.org/10.1155/2019/3140204
_version_ 1783395985179803648
author Shimizu, Masaki
Inoue, Natsumi
Mizuta, Mao
Nakagishi, Yasuo
Yachie, Akihiro
author_facet Shimizu, Masaki
Inoue, Natsumi
Mizuta, Mao
Nakagishi, Yasuo
Yachie, Akihiro
author_sort Shimizu, Masaki
collection PubMed
description To investigate whether serum leucine-rich α2-glycoprotein (LRG) levels are useful as a marker of disease activity in systemic juvenile idiopathic arthritis (s-JIA), we determined serum LRG levels in fifty-nine s-JIA patients, 15 with other subtypes of JIA, 7 with Kawasaki disease (KD), 7 with influenza A infection (flu), 7 with enterohemorrhagic Escherichia coli (EHEC) infection, and 20 healthy controls (HC). Results were compared with the clinical features of s-JIA and serum cytokine levels including interleukin- (IL-) 6, IL-18, and soluble tumor necrosis factor receptors I and II. Serum LRG levels in active s-JIA were higher compared to those in other subtypes of JIA, EHEC, flu patients, and HC. Serum LRG levels were normalized in the inactive s-JIA phase after treatment. Serum LRG levels were positively correlated with serum C-reactive protein and ferritin levels. Serum LRG levels reflected s-JIA disease activity and thus may be useful for monitoring s-JIA disease activity.
format Online
Article
Text
id pubmed-6378769
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63787692019-03-12 Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis Shimizu, Masaki Inoue, Natsumi Mizuta, Mao Nakagishi, Yasuo Yachie, Akihiro J Immunol Res Research Article To investigate whether serum leucine-rich α2-glycoprotein (LRG) levels are useful as a marker of disease activity in systemic juvenile idiopathic arthritis (s-JIA), we determined serum LRG levels in fifty-nine s-JIA patients, 15 with other subtypes of JIA, 7 with Kawasaki disease (KD), 7 with influenza A infection (flu), 7 with enterohemorrhagic Escherichia coli (EHEC) infection, and 20 healthy controls (HC). Results were compared with the clinical features of s-JIA and serum cytokine levels including interleukin- (IL-) 6, IL-18, and soluble tumor necrosis factor receptors I and II. Serum LRG levels in active s-JIA were higher compared to those in other subtypes of JIA, EHEC, flu patients, and HC. Serum LRG levels were normalized in the inactive s-JIA phase after treatment. Serum LRG levels were positively correlated with serum C-reactive protein and ferritin levels. Serum LRG levels reflected s-JIA disease activity and thus may be useful for monitoring s-JIA disease activity. Hindawi 2019-02-04 /pmc/articles/PMC6378769/ /pubmed/30863782 http://dx.doi.org/10.1155/2019/3140204 Text en Copyright © 2019 Masaki Shimizu et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Shimizu, Masaki
Inoue, Natsumi
Mizuta, Mao
Nakagishi, Yasuo
Yachie, Akihiro
Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis
title Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis
title_full Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis
title_fullStr Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis
title_full_unstemmed Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis
title_short Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis
title_sort serum leucine-rich α2-glycoprotein as a biomarker for monitoring disease activity in patients with systemic juvenile idiopathic arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378769/
https://www.ncbi.nlm.nih.gov/pubmed/30863782
http://dx.doi.org/10.1155/2019/3140204
work_keys_str_mv AT shimizumasaki serumleucinericha2glycoproteinasabiomarkerformonitoringdiseaseactivityinpatientswithsystemicjuvenileidiopathicarthritis
AT inouenatsumi serumleucinericha2glycoproteinasabiomarkerformonitoringdiseaseactivityinpatientswithsystemicjuvenileidiopathicarthritis
AT mizutamao serumleucinericha2glycoproteinasabiomarkerformonitoringdiseaseactivityinpatientswithsystemicjuvenileidiopathicarthritis
AT nakagishiyasuo serumleucinericha2glycoproteinasabiomarkerformonitoringdiseaseactivityinpatientswithsystemicjuvenileidiopathicarthritis
AT yachieakihiro serumleucinericha2glycoproteinasabiomarkerformonitoringdiseaseactivityinpatientswithsystemicjuvenileidiopathicarthritis